Safety and Tolerability of the Glutamate Antagonist CGS 19755 (Selfotel) in Patients With Acute Ischemic Stroke
- 1 April 1995
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Stroke
- Vol. 26 (4), 602-605
- https://doi.org/10.1161/01.str.26.4.602
Abstract
Background and Purpose CGS 19755 is a competitive N -methyl- d -aspartate (NMDA) receptor antagonist that limits neuronal damage in animal stroke models. The objectives of this multicenter (7 centers), randomized, double-blind, placebo-controlled, ascending-dose phase IIa study were to evaluate the safety and tolerability of CGS 19755 and obtain pharmacokinetic and preliminary data on its efficacious dose range in patients treated within 12 hours of hemispheric ischemic stroke. Methods At each dose level, 6 patients were randomized to one or two intravenous bolus doses of CGS 19755, and 2 patients were randomized to placebo. An unblinded safety and monitoring committee evaluated results at each dose before ascending to the next level. All patients at the first level (1 mg/kg) received two doses separated by 12 hours. The first 2 patients at 2 mg/kg received two doses, but adverse experiences occurred in both; subsequent patient groups received single doses of 2.0, 1.75, or 1.5 mg/kg. Results Adverse experiences (agitation, hallucinations, confusion, paranoia, and delirium) occurred in all 6 patients treated with 2 mg/kg, and in 3 of 5 at 1.75 mg/kg. Similar but milder adverse experiences were noted in 4 of 7 patients at 1.5 mg/kg and 1 of 6 patients at 1.0 mg/kg. Adverse experiences began between 20 minutes and 22 hours (mean, 8 hours) after treatment and lasted 2 to 60 hours (mean, 24 hours). Mortality was 1 of 8 in patients receiving placebo and 3 of 24 in treated patients. In treated survivors, median and mean percent improvement in National Institutes of Health Stroke Scale scores from baseline to terminal visit (mean, 86 days) was comparable at all doses, and 95% of treated patients had Barthel Index scores of ≥70 at the terminal visit. Conclusions We conclude that a single intravenous dose of 1.5 mg/kg CGS 19755 is safe and tolerable in patients with acute ischemic stroke. An efficacy trial is indicated.Keywords
This publication has 8 references indexed in Scilit:
- Neuroprotective Effects of Glutamate Antagonists and Extracellular AcidityScience, 1993
- The Effects of a Competitive NMDA Receptor Antagonist (CGS-19755) on Cerebral Blood Flow and pH in Focal IschemiaJournal of Cerebral Blood Flow & Metabolism, 1991
- N‐Methyl‐D‐Aspartate antagonist reduces stroke size and regional glucose metabolismAnnals of Neurology, 1990
- CGS‐19755, A competitive NMDA receptor antagonist, reduces calcium‐calmodulin binding and improves outcome after global cerebral ischemiaAnnals of Neurology, 1990
- Changes in extracellular amino acid neurotransmitters produced by focal cerebral ischemiaNeuroscience Letters, 1990
- The N-methyl-d-aspartate antagonists CGS 19755 and CPP reduce ischemic brain damage in gerbilsBrain Research, 1988
- Glutamate and the pathophysiology of hypoxic–ischemic brain damageAnnals of Neurology, 1986
- Glutamate neurotoxicity in cortical cell culture is calcium dependentNeuroscience Letters, 1985